Búsqueda | Portal de Búsqueda de la BVS Ecuador

1.

ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0.

Kiesewetter, B; Dafni, U; de Vries, E G E; Barriuso, J; Curigliano, G; González-Calle, V; Galotti, M; Gyawali, B; Huntly, B J P; Jäger, U; Latino, N J; Malcovati, L; Oosting, S F; Ossenkoppele, G; Piccart, M; Raderer, M; Scarfò, L; Trapani, D; Zielinski, C C; Wester, R; Zygoura, P; Macintyre, E; Cherny, N I.

Ann Oncol ; 34(9): 734-771, 2023 09.

Artículo en Inglés | MEDLINE | ID: mdl-37343663

2.

Dexamethasone as a partner of isatuximab.

Mateos, M V; González-Calle, V.

Blood ; 137(9): 1133-1134, 2021 03 04.

Artículo en Inglés | MEDLINE | ID: mdl-33661291

3.

The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression.

Medina-Herrera, A; Vazquez, I; Cuenca, I; Rosa-Rosa, J M; Ariceta, B; Jimenez, C; Fernandez-Mercado, M; Larrayoz, M J; Gutierrez, N C; Fernandez-Guijarro, M; Gonzalez-Calle, V; Rodriguez-Otero, P; Oriol, A; Rosiñol, L; Alegre, A; Escalante, F; De La Rubia, J; Teruel, A I; De Arriba, F; Hernandez, M T; Lopez-Jimenez, J; Ocio, E M; Puig, N; Paiva, B; Lahuerta, J J; Bladé, J; San Miguel, J F; Mateos, M V; Martinez-Lopez, J; Calasanz, M J; Garcia-Sanz, R.

Blood Cancer J ; 14(1): 74, 2024 Apr 29.

Artículo en Inglés | MEDLINE | ID: mdl-38684670

4.

Prevention of venous thromboembolism in hematologic neoplasms: an expert consensus from SEHH-SETH.

Gonzalez-Porras, J R; Mateo, J; Gonzalez-Calle, V; Marco, P; Garcia-Gutierrez, V; Reverter, J C; Lecumberri, R.

Clin Transl Oncol ; 24(5): 770-783, 2022 May.

Artículo en Inglés | MEDLINE | ID: mdl-34850351

5.

Prevention of venous thromboembolism in hematologic neoplasms: an expert consensus from SEHHSETH

González-Porras, José Ramón; Mateo, J; González-Calle, V; Marco, P; García-Gutiérrez, V; Reverter, J. C..

Clin. transl. oncol. (Print) ; 24(5): 770-783, mayo 2022.

Artículo en Inglés | IBECS (España) | ID: ibc-203780

6.

Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma.

González-Calle, V; Dávila, J; Escalante, F; de Coca, A G; Aguilera, C; López, R; Bárez, A; Alonso, J M; Hernández, R; Hernández, J M; de la Fuente, P; Puig, N; Ocio, E M; Gutiérrez, N C; García-Sanz, R; Mateos, M V.

Leukemia ; 30(10): 2026-2031, 2016 10.

Artículo en Inglés | MEDLINE | ID: mdl-27133826

Portal de Búsqueda de la BVS Ecuador

Información y Conocimiento para la Salud

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar:

ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0.

Dexamethasone as a partner of isatuximab.

The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression.

Prevention of venous thromboembolism in hematologic neoplasms: an expert consensus from SEHH-SETH.

Prevention of venous thromboembolism in hematologic neoplasms: an expert consensus from SEHHSETH

Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma.

Portal de Búsqueda de la BVS Ecuador

Información y Conocimiento para la Salud

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar:

ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0.

Dexamethasone as a partner of isatuximab.

The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression.

Prevention of venous thromboembolism in hematologic neoplasms: an expert consensus from SEHH-SETH.

Prevention of venous thromboembolism in hematologic neoplasms: an expert consensus from SEHHSETH

Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma.

Prevention of venous thromboembolism in hematologic neoplasms: an expert consensus from SEHHSETH